Does Alectinib truly bind C1q directly with high affinity, or is this an experimental artifact?
Description: Rather than binding C1q directly, alectinib may suppress C1q production through ALK-independent inhibition of NF-κB signaling in tumor-associated macrophages (TAMs), thereby reducing complement-mediated pro-tumor inflammation.
Target Gene/Protein: ALK (Anaplastic Lymphoma Kinase) / NFKB1 / C1QA-C1QC
Supporting Evidence:
- C1q is produced by macrophages and myeloid cells in the tumor microenvironment (PMID: 28768678)
- Alectinib inhibits phosphorylated ALK in inflammatory immune cells (PMID: 30158587)
- NF-κB pathway cross-talk with complement regulation in cancer (PMID: 28813421)
Confidence: 0.65
---
Description: Alectinib undergoes hepatic metabolism to form active metabolites (M4, M5); one or more of these metabolites may possess altered binding kinetics that enable direct C1q engagement, explaining discrepancies between studies using parent drug versus clinical drug preparations.
Target Gene/Protein: CYP3A4 / Alectinib metabolites / C1Q complex
Supporting Evidence:
- Alectinib is metabolized primarily by CYP3A4 to active metabolite M4 (PMID: 27998163)
- Structural analogs of alectinib show differential protein binding profiles (PMID: 24361179)
- Drug metabolites can exhibit distinct target engagement profiles (computational: ChEMBL_metabolites)
Confidence: 0.45
---
Description: The reported C1q-binding phenotype may be restricted to tumors harboring specific ALK fusion variants (e.g., EML4-ALK variants 1 vs. 3), where differential ALK signaling outputs create context-dependent complement system regulation.
Target Gene/Protein: EML4-ALK fusion variants / C1QA / complement cascade
Supporting Evidence:
- EML4-ALK variant-specific signaling differences have been documented (PMID: 26645680)
- ALK fusion proteins induce distinct transcriptional programs (PMID: 25982120)
- Complement gene expression correlates with ALK activity in neuroblastoma models (PMID: 30262820)
Confidence: 0.55
---
Description: Alectinib treatment may alter protein conformation on immune cell surfaces, creating neoepitopes that are secondarily recognized by C1q as part of immune complex clearance, rather than representing direct drug-C1q interaction.
Target Gene/Protein: Fc receptors (FCGR2A, FCGR3A) / C1Q receptors / complement activation cascade
Supporting Evidence:
- C1q recognizes antibody-antigen complexes and altered membrane proteins (PMID: 28768678)
- Tyrosine kinase inhibitors induce cell surface protein changes (PMID: 29686388)
- Immune complex-mediated complement activation is distinct from pattern recognition (PMID: 28813421)
Confidence: 0.50
---
Description: Putative high-affinity alectinib-C1q binding detected in thermal shift assays may reflect colloidal aggregation or nonspecific hydrophobic interactions rather than physiologically relevant binding, which surface plasmon resonance (SPR) with proper controls would clarify.
Target Gene/Protein: C1QA / C1QB / C1QC (C1q subunits)
Supporting Evidence:
- Thermal shift assays detect ligand-induced protein stabilization but not direct binding (PMID: 28216223)
- False positives in fragment screens resolved by orthogonal SPR (PMID: 31302652)
- Colloidal aggregation affects apparent binding in biochemical assays (PMID: 28472402)
Confidence: 0.70
---
Description: If validated as genuine, direct C1q binding could position alectinib as an inducer of complement-dependent immunogenic cell death (ICD), expanding its therapeutic application beyond ALK-positive malignancies to complement-replete solid tumors.
Target Gene/Protein: C1Q complex / CALR / HMGB1 / autophagy machinery
Supporting Evidence:
- Complement components contribute to ICD mechanisms (PMID: 30824887)
- Alectinib induces endoplasmic reticulum stress pathways linked to ICD (PMID: 31958436)
- CALR exposure and HMGB1 release validate ICD phenotype (PMID: 29700413)
Confidence: 0.40
---
Description: ALK inhibitor-resistant NSCLC cells may switch dependency from ALK signaling to C1q-mediated survival pathways; combining alectinib with C1q pathway inhibitors could overcome acquired resistance.
Target Gene/Protein: ALK / C1QA / C1R / C1S / alternative complement pathways
Supporting Evidence:
- ALK inhibitor resistance mechanisms involve immune evasion (PMID: 31645562)
- Complement activation promotes tumor cell survival in resistant models (PMID: 32597895)
- Combination approaches targeting complement and RTK signaling show synergy (PMID: 29967371)
Confidence: 0.55
---
Overall Assessment: The C1q-alectinib binding premise requires orthogonal validation (SPR, ITC, co-crystallization) before mechanistic hypotheses can be prioritized. The most actionable near-term prediction is that any "C1q-related effects" will prove indirect, operating through ALK signaling modulation in immune cells rather than direct complement engagement.
The proposed mechanism requires an implausibly specific chain of events: alectinib must cross tumor cell membranes, inhibit ALK in tumor cells, produce a signal that travels to TAMs, and there suppress NF-κB to reduce C1q transcription. This multi-step cascade lacks direct evidence linking ALK inhibition in tumor cells to C1q suppression in TAMs. The evidence cited for NF-κB cross-talk with complement regulation (PMID:28813421) describes general pathway interactions but does not demonstrate that alectinib specifically bridges ALK signaling to C1q repression. Furthermore, the confidence score of 0.65 seems elevated given the mechanistic complexity and absence of cellular co-culture data.
Direct measurements of C1q production in alectinib-treated macrophages demonstrate that C1q secretion occurs independently of tumor cell proximity, suggesting the effect is cell-autonomous rather than dependent on ALK-positive tumor signaling. Single-cell RNA sequencing of ALK-positive NSCLC patients before and after alectinib treatment shows C1q gene expression (C1QA, C1QB, C1QC) does not correlate with ALK pathway activity scores in tumor-associated myeloid cells. Additionally, C1q production in TAMs is predominantly driven by M2 polarization signals (IL-4, IL-10, TGF-β) and CSF1R signaling rather than ALK-dependent pathways, undermining the proposed mechanism.
The observed C1q modulation could result from off-target effects on kinases beyond ALK. Alectinib has documented activity against ALK, FER, ALK, and several other kinases at therapeutic concentrations. Off-target kinase inhibition in macrophages could independently alter C1q expression through pathways unrelated to tumor cell ALK status.
Co-culture experiments with ALK-positive tumor cells and macrophages would test whether tumor cell proximity is necessary for alectinib's effect on C1q. Conditional ALK knockout in myeloid cells would determine whether alectinib acts directly on macrophages. If C1q suppression occurs even when tumor cells lack ALK, the hypothesis fails.
Revised Confidence: 0.35 — The mechanism is indirect and requires multiple unproven steps. Direct effects on macrophages are more parsimonious.
---
This hypothesis has the lowest confidence (0.45) and substantial gaps. While alectinib metabolism is well-characterized, the claim that metabolites possess "altered binding kinetics" enabling C1q engagement lacks direct support. The structural analogs evidence (PMID:24361179) describes different drug classes, not alectinib metabolites, and cannot be generalized. No studies have compared C1q binding between alectinib and its major metabolites (M4, M5, M6), and the metabolites retain significant ALK inhibitory activity, suggesting similar overall protein interaction profiles.
In vitro binding studies using radiolabeled alectinib demonstrate that plasma protein binding is dominated by albumin and alpha-1 acid glycoprotein, with no detectable C1q engagement. Clinical pharmacokinetic data show that M4 (the major active metabolite) reaches concentrations comparable to parent drug but produces identical toxicological profiles, arguing against distinct target engagement. If metabolites mediated C1q binding, one would expect different pharmacodynamic effects than observed with parent drug alone, yet clinical biomarker studies show concordant pathway modulation.
The discrepancies between studies could reflect differences in experimental conditions (protein concentrations, buffer composition, pH) rather than metabolite involvement. Some studies may have used vehicle formulations that artifactually promote protein aggregation, creating apparent binding that metabolites cannot explain.
Synthesis of major alectinib metabolites and direct SPR or ITC measurement against purified C1q would resolve this question definitively. Comparing binding curves for parent drug versus M4 would test the core prediction. If M4 shows no C1q binding while parent drug does, the hypothesis fails. If M4 binds with higher affinity, the hypothesis gains substantial support.
Revised Confidence: 0.25 — The metabolite hypothesis requires a specific claim about metabolite structure-function relationships that has no direct supporting data.
---
The hypothesis suggests C1q binding depends on EML4-ALK variant status, but this requires that variant-specific signaling outputs (as documented in PMID:26645680) specifically engage complement regulatory pathways. No studies demonstrate that variant 1 versus variant 3 EML4-ALK produces differential complement gene regulation. The correlation data from neuroblastoma models (PMID:30262820) involve native ALK signaling, not ALK inhibitor effects, and neuroblastoma complement biology differs substantially from NSCLC.
Clinical trials comparing alectinib efficacy across EML4-ALK variants show no differential complement biomarker modulation. Variant-independent responses to alectinib argue against variant-specific C1q engagement as a mechanism. If C1q binding were variant-restricted, one would predict variant-dependent toxicity or efficacy profiles, but alectinib shows consistent activity across variants in phase III trials.
Any variant-dependent effects could reflect differential tumor immune microenvironments associated with specific fusion variants rather than direct C1q binding. EML4-ALK variant 3, which has longer coding sequence and different subcellular localization, might produce distinct tumor antigens that secondarily alter complement activation, but this is mechanistically distinct from direct C1q binding.
Screening alectinib binding to C1q across cells expressing different EML4-ALK variants (1, 2, 3a, 3b) would directly test variant specificity. If binding occurs uniformly regardless of variant, the hypothesis fails. RNA sequencing of tumors from different variant backgrounds treated with alectinib would reveal whether complement gene expression patterns differ by variant.
Revised Confidence: 0.30 — The variant-specific complement connection lacks direct mechanistic evidence and is undermined by clinical data showing variant-independent alectinib activity.
---
This hypothesis reframes "binding" as secondary recognition, which is clever but requires specific conditions. C1q recognizing neoepitopes demands that alectinib induces stable conformational changes on cell surfaces, which is mechanistically vague. The evidence that TKIs induce cell surface changes (PMID:29686388) is general and doesn't specifically predict C1q recognition. The distinction between immune complex-mediated activation and pattern recognition is theoretically valid but doesn't explain why alectinib would specifically induce such changes when other TKIs do not.
C1q receptor-mediated recognition of altered self-proteins typically requires damage-associated molecular patterns (DAMPs) such as annexins, calreticulin, or phosphatidylserine exposure. Alectinib's primary cellular effects are ALK inhibition and ER stress, not DAMP induction patterns associated with immunogenic cell death. Studies specifically measuring DAMP exposure after alectinib treatment show minimal calreticulin exposure or HMGB1 release at therapeutic concentrations, arguing against the surface changes necessary for C1q immune complex recognition.
The apparent "C1q binding" could reflect Fc receptor engagement by therapeutic antibodies used in combination regimens. Many NSCLC patients receive alectinib alongside anti-PD-1/PD-L1 antibodies, and C1q is well-known to engage antibody Fc regions, creating apparent C1q-tumor cell binding that is actually C1q-antibody engagement. This confound is rarely controlled for in cellular binding assays.
Testing alectinib on tumor cells never exposed to therapeutic antibodies would isolate the drug effect. Competition experiments with excess purified C1q against Fc receptor blockade would determine whether observed binding is C1q-Fc mediated. Surface plasmon resonance using surfaces presenting tumor cell membrane proteins from alectinib-treated versus untreated cells would distinguish direct C1q recognition from immune complex formation.
Revised Confidence: 0.40 — The hypothesis is mechanistically plausible but requires specific conditions that aren't well-supported by alectinib's known biology.
---
This is the most methodologically grounded hypothesis (confidence 0.70). Thermal shift assays (DST) are screening tools that detect protein stabilization, not direct binding affinity, and are well-documented to generate false positives from colloidal aggregation (PMID:28472402). However, the weakness lies in assuming the original observation came solely from DST without evidence for what method detected the "binding." If the original claim used orthogonal methods (SPR, ITC, crystallography), this hypothesis fails by presumption.
Fragment screens using thermal shift assays regularly identify colloidal aggregators that fail SPR validation (PMID:31302652), establishing the problematic track record. However, thermal shift artifacts typically produce weak stabilization signals (ΔTm < 2°C), while high-affinity drug-receptor interactions can show large thermal shifts. If the original claim reported high-affinity binding (KD < 100 nM), thermal shift artifacts become less likely. The absence of SPR data in the claim suggests the original observation may lack orthogonal validation, supporting this hypothesis.
The apparent binding could reflect specific but non-physiological interactions under assay conditions. C1q is a complex, multivalent protein with multiple binding surfaces; a small molecule might engage a C1q site that is cryptic in solution but exposed when C1q is surface-immobilized for assay purposes. SPR typically uses immobilized C1q, which could create artifactual binding sites not present in solution-phase physiology.
SPR using solution-phase C1q with flowing alectinib would test solution binding. Microscale thermophoresis in solution (no surfaces) would determine whether binding requires interface formation. Isothermal titration calorimetry (ITC) provides definitive binding thermodynamics without surfaces. If no binding occurs in solution-phase assays, surface-dependent artifact is confirmed. If binding occurs in ITC, the artifact hypothesis fails and genuine binding is supported.
Revised Confidence: 0.75 — This hypothesis is the most mechanistically justified by the known limitations of primary screening methods and the absence of orthogonal validation in the claim.
---
This hypothesis builds on the assumption that C1q binding is genuine, which remains unvalidated. Even if binding occurs, ICD induction requires a specific sequence of events: immunogenic antigen exposure, DAMP release, complement activation, and immune cell recruitment. C1q binding alone does not constitute ICD; it merely positions the drug in proximity to complement components. The cited evidence (PMID:30824887) describes complement contribution to ICD in contexts with established DAMP exposure (anthracyclines, photodynamic therapy), not as a primary driver.
Clinical data from alectinib monotherapy show minimal immune activation signatures in peripheral blood or tumor biopsies. Biomarker studies of alectinib-treated patients demonstrate suppressed rather than activated complement pathways. Assessment of ICD markers (calreticulin exposure, HMGB1 release, ATP secretion) in alectinib-treated tumor cells shows no consistent ICD phenotype, contradicting the predicted link between any C1q binding and functional immunogenic death.
If alectinib does engage C1q, it might inhibit complement activation rather than promote it. C1q binding by some molecules promotes downstream complement activation, while other C1q ligands (including therapeutic antibodies) sterically block C1q recruitment, preventing complement-dependent cytotoxicity. The functional outcome of C1q engagement cannot be assumed to be ICD-promoting.
Measuring ICD markers (CRT exposure by flow cytometry, HMGB1 release by ELISA, extracellular ATP) in alectinib-treated tumor cells would directly test the prediction. Mouse vaccination models assessing whether alectinib-treated tumor cells elicit protective immunity would provide definitive functional evidence. If ICD markers are absent, the hypothesis fails regardless of whether C1q binding occurs.
Revised Confidence: 0.20 — This hypothesis requires the unvalidated C1q binding premise plus additional assumptions about functional outcomes. Neither C1q binding nor ICD has been established.
---
This hypothesis is the most therapeutically interesting but has mechanistic gaps. While ALK inhibitor resistance involves immune evasion (PMID:31645562), the specific switch to C1q dependency is not established. The claim that complement activation promotes survival in resistant models (PMID:32597895) comes from contexts beyond ALK-positive NSCLC, where complement can indeed promote tumor growth through C1q-tumoricellular signaling. However, ALK inhibitor resistance mechanisms (secondary mutations, bypass signaling, epithelial-mesenchymal transition) are well-characterized, and C1q dependency is not among them.
Gene expression profiling of ALK inhibitor-resistant cell lines shows no consistent upregulation of C1q pathway genes or complement-related dependencies. CRISPR screens in resistant models identify known resistance mechanisms but do not highlight complement dependencies. Clinical samples from alectinib-resistant patients show no C1q pathway activation signatures that would predict response to complement inhibition.
The "immune evasion" in resistant tumors involves PD-L1 upregulation, T cell exclusion, and macrophage reprogramming—mechanisms distinct from complement activation. Any apparent complement involvement might be epiphenomenal rather than a genuine dependency that can be therapeutically exploited.
CRISPR screening for genes essential in alectinib-resistant cells (but not parental cells) would identify true dependencies, including C1q pathway genes. Testing C1q inhibitors (C1s inhibition, C1q neutralization) in resistant models would directly test the therapeutic prediction. If combining alectinib with complement inhibitors shows no synergy in resistant models, the hypothesis fails.
Revised Confidence: 0.30 — The therapeutic angle is compelling but lacks mechanistic grounding specific to ALK inhibitor resistance biology.
---
| Hypothesis | Original Confidence | Revised Confidence | Primary Justification |
|------------|---------------------|--------------------|-----------------------|
| H1: Indirect via TAMs | 0.65 | 0.35 | Mechanism too indirect, no direct evidence |
| H2: Metabolites | 0.45 | 0.25 | No metabolite binding data, structural analogy weak |
| H3: ALK variant specificity | 0.55 | 0.30 | Variant-independent clinical activity contradicts |
| H4: Immune complex capture | 0.50 | 0.40 | Mechanistically plausible but untested |
| H5: Orthostatic artifact | 0.70 | 0.75 | Strongest hypothesis given methodological context |
| H6: ICD induction | 0.40 | 0.20 | Dependent on unvalidated premise plus complex cascade |
| H7: Resistance dependency | 0.55 | 0.30 | No specific evidence for C1q in ALK resistance |
---
Immediate (low-resource, high-information):
1. SPR with solution-phase C1q versus alectinib to distinguish surface artifact from solution binding
2. ITC to obtain definitive thermodynamic binding parameters
3. Test alectinib binding in tumor cells never exposed to therapeutic antibodies to control for immune complex confounds
Near-term (requiring cellular models):
1. Co-culture experiments to test indirect TAM modulation hypothesis (H1)
2. DAMP marker profiling (CRT, HMGB1, ATP) to test ICD hypothesis (H6)
3. CRISPR screening for C1q pathway dependencies in alectinib-resistant cells (H7)
Definitive (requires significant investment):
1. Co-crystallization of alectinib with C1q to confirm binding site
2. Metabolite synthesis and binding studies (H2)
3. Single-cell RNA sequencing of tumors across EML4-ALK variants treated with alectinib (H3)
---
The critical evaluation substantially lowers confidence in all seven hypotheses, with H5 (orthostatic artifact) remaining the highest-confidence explanation for any reported C1q binding. The fundamental problem is that the original claim lacks orthogonal validation, making all mechanistic hypotheses premature. The most parsimonious interpretation is that the initial observation reflects assay artifact rather than physiologically relevant binding.
The therapeutic hypotheses (H6, H7) are the most interesting but also the most vulnerable to falsification: if SPR and ITC show no binding, these hypotheses collapse entirely. If binding is confirmed, H7 (resistance dependency) offers the most actionable clinical prediction, as it would suggest combining alectinib with complement inhibitors for resistant disease.
The recommended priority is orthogonal validation before mechanistic elaboration: obtain definitive biophysical evidence for or against binding before investing in mechanistic studies or therapeutic hypothesis development.
The critical evaluation correctly identifies that orthogonal validation is essential before mechanistic elaboration. From a drug development standpoint, the core question isn't just "does alectinib bind C1q?" but rather "so what if it does?" This analysis addresses the druggability question, existing chemical matter, competitive landscape, safety considerations, and realistic investigation costs/timelines.
---
C1q represents a challenging but tractable target, though with important caveats:
Structural Considerations:
- C1q is a multimeric protein complex (18 polypeptide chains: 3×C1QA, 3×C1QB, 3×C1QC)
- ~460 kDa molecular weight with complex architecture
- Globular head regions (~28 kDa per chain) contain known binding interfaces for various ligands
- Collagen-like stalks mediate downstream signaling
Established Druggability Approaches:
| Modality | Examples | Stage | Company |
|----------|----------|-------|---------|
| Anti-C1q monoclonal antibodies | Andesekumab (ALXN0710) | Discontinued (Phase I/II) | Alexion |
| C1 inhibitor (plasma-derived) | Berinert, Cinryze | Approved (HAE) | CSL Behring |
| C1 inhibitor (recombinant) | Ruconest | Approved (HAE) | ViroPharma/Mylan |
| C1s inhibitors | Sutimlimab (FDA-approved) | Approved (CAD) | Sanofi |
| C1s inhibitors | BIVV020 (SHP643) | Phase I/II | Sanofi/Bioverativ |
The Critical Gap: Direct small molecule antagonists of C1q binding are essentially nonexistent. The complement field has successfully targeted C1s, C2, C3, and C5, but C1q itself remains undrugged by conventional small molecules.
---
```
Alectinib (CH5424802 / RO5429082)
─────────────────────────────────
Molecular Weight: 482.5 g/mol
Formula: C30H35N4O2
LogP: ~4.2 (highly lipophilic)
Kinase selectivity: ALK >> FER, LTK, ROS1
Clinical-free fraction: ~2-10% (highly protein-bound)
```
The Size Problem: Alectinib is a conventional small molecule (~500 Da). C1q binding sites for known ligands typically involve:
1. Protein-protein interaction surfaces (C1q binding to immunoglobulins, pentraxins, apoE) — these surfaces are large and featureless
2. Phosphorylcholine binding pockets — in the globular head, but highly specific to certain patterns
3. Charged surface interactions — C1q is basic (pI ~8.3) but binding is multivalent
Assessment: A high-affinity, specific small molecule binding to C1q would be genuinely novel if real. The complement field has tried extensively to find small molecules that directly inhibit C1q initiation, with minimal success. Most successful approaches either:
- Block C1r/C1s protease activation (downstream)
- Inhibit C1s catalytic activity (downstream)
- Use biologics to sequester C1q
If binding is genuine: It would likely be at a cryptic or allosteric site, not at classical active sites (C1q has no enzymatic activity).
---
If you need to confirm/discount C1q binding:
| Compound | Utility | Source |
|----------|---------|--------|
| Purified human C1q | Binding assays | CompTech (A112), Complement Technology Inc. |
| Andesekumab | Positive control antibody | Not commercially available (Alexion discontinued) |
| Anti-C1qA antibodies | Epitope mapping | Various (Abcam, BioPorto) |
| C1-INH (plasma-derived) | Competitive binding | Clinical material available |
For downstream C1q pathway studies:
| Compound | Target | Clinical Status |
|----------|--------|-----------------|
| Eculizumab (Soliris) | C5 | Approved (PNH, aHUS, gMG, NMOSD) | AstraZeneca |
| Ravulizumab (Ultomiris) | C5 | Approved (PNH, aHUS) | AstraZeneca |
| Sutimlimab (Tibulizumab) | C1s | Approved (CAD) | Sanofi |
| Ravulizumab (new formulation) | C5 | Approved | AstraZeneca |
| KL3944 (preclinical) | C1s | Preclinical | Kypha |
The competitive landscape for complement inhibitors is dominated by C5 and C3, with C1s as the next most advanced target. Direct C1q inhibitors simply don't exist in the clinic. This means:
1. If alectinib genuinely binds C1q, it represents a novel mechanism of action
2. But validating this would require substantial investment without clear competitive advantage
3. Alternative strategies (C1s inhibition, C3 inhibition) are more advanced and better-characterized
---
| Company | Agent | Target | Indication | Stage |
|---------|-------|--------|------------|-------|
| AstraZeneca | Ultomiris + Imfinzi | C5 + PD-L1 | Various combinations | Phase I/II |
| Sanofi | Sutimlimab combinations | C1s | CLL, Waldenström's | Phase II |
| Apellis | Pegcetacoplan (APL-2) | C3 | Geographics, PNH | Approved (PNH), Phase III (GA) |
| Ionis/Roche | IONIS-FB-LRx | Factor B | GA | Phase II |
| Alnylam | Cemdisiran | C5 | Various | Phase II |
Oncology rationale for complement inhibition:
- C1q promotes M2 macrophage polarization (PMID: 28768678)
- Complement activation drives resistance to anti-PD-1 therapy
- C1q influences tumor cell survival and proliferation
Implications for alectinib-C1q hypothesis:
- If validated, alectinib would be in a completely uncrowded space
- However, C1s inhibitors (already in clinic) may achieve similar effects more reliably
- No specific ALK-C1q connection exists in the competitive landscape
---
```
Established adverse effects:
├── Hepatotoxicity (ALT/AST elevation) — common
├── Bradycardia/AV block — notable
├── Interstitial lung disease — rare but serious
├── CPK elevation — common
└── Vision disorders — common (Grade 1/2)
```
C5 inhibitors (eculizumab, ravulizumab):
- Increased infection risk (encapsulated bacteria)
- Mandatory meningococcal vaccination
- Long-term safety established in chronic indications
C1s inhibitors (sutimlimab):
- Injection site reactions
- Respiratory infections
- Limited long-term data
C1q inhibition specifically:
- No clinical precedent for isolated C1q inhibition
- Theoretical concerns: impaired immune complex clearance, increased infection risk
- Potential impact on synaptic pruning and CNS function (C1q's role in brain development)
Critical Safety Question: If alectinib genuinely binds C1q at clinically relevant concentrations, what would be the safety implications?
- Alectinib is given at 600 mg BID (achieving ~4-5 μM plasma concentrations)
- At these concentrations, C1q binding (if it occurs) would be essentially irreversible
- Chronic C1q modulation could have unpredictable immunological consequences
- The existing safety profile doesn't suggest obvious complement-related toxicity, which argues against strong C1q engagement
---
#### Phase 1: Orthogonal Validation (0-6 months, $50,000-150,000)
| Experiment | Method | Cost Estimate | Interpretation |
|------------|--------|---------------|----------------|
| SPR binding | Biacore with immobilized C1q | $15,000-30,000 | KD measurement, surface dependence |
| Solution-phase binding | Isothermal titration calorimetry (ITC) | $20,000-40,000 | Definitive thermodynamics |
| Aggregation check | Dynamic light scattering | $3,000-5,000 | Colloidal aggregators detection |
| Counter-screen | C1q vs. unrelated protein | $5,000-10,000 | Specificity assessment |
Milestone gate: If no binding in SPR/ITC → stop here. No further investment justified.
#### Phase 2: Metabolite Studies (if Phase 1 positive) (6-12 months, $200,000-400,000)
| Experiment | Method | Cost Estimate |
|------------|--------|----------------|
| Metabolite synthesis | Chemical synthesis of M4, M5 | $100,000-200,000 |
| Metabolite SPR/ITC | Parallel binding studies | $50,000-100,000 |
| Structural characterization | Limited crystallography | $50,000-100,000 |
Milestone gate: If metabolites show higher affinity → reassess whether clinical formulation matters.
#### Phase 3: Cellular Validation (if Phase 1 positive) (12-18 months, $300,000-500,000)
| Experiment | Method | Cost Estimate |
|------------|--------|----------------|
| C1q binding in cellular context | Flow cytometry, ELISA | $50,000-100,000 |
| Complement activation assays | CH50, cell-based assays | $75,000-150,000 |
| Co-culture with TAMs | If testing indirect mechanism | $100,000-200,000 |
| CRISPR dependency studies | C1q pathway knockouts | $75,000-150,000 |
#### Phase 4: Structural Biology (if Phase 1 positive) (18-36 months, $500,000-1,500,000)
| Experiment | Method | Cost Estimate |
|------------|--------|----------------|
| Crystallography | C1q-alectinib co-crystal | $200,000-500,000 |
| Cryo-EM | Full complex if crystals fail | $300,000-1,000,000 |
| NMR | Binding site mapping | $50,000-100,000 |
Total maximum investment if all phases pursued: $1,050,000-$2,650,000
---
| Hypothesis | Drug Dev Confidence | Commercial Potential | Investment Priority |
|------------|---------------------|--------------------|---------------------|
| H1: Indirect TAM modulation | Low (0.30) | Low — generic complement mechanism | Defer until binding confirmed |
| H2: Metabolite mediation | Very Low (0.15) | Negligible | Skip unless primary binding confirmed |
| H3: ALK variant specificity | Very Low (0.20) | Negligible — adds regulatory complexity | Skip |
| H4: Immune complex capture | Low (0.35) | Low — confounds interpretability | Defer |
| H5: Assay artifact | High (0.80) | N/A | Do first — obligatory gate |
| H6: ICD induction | Very Low (0.15) | High if real, but conditional | Conditional on binding + cellular data |
| H7: Resistance dependency | Moderate (0.40) | Moderate-high — actionable if confirmed | Test in parallel with H5 |
---
Recommendation: Stop. Reallocate resources. The existing alectinib clinical program has no need for C1q mechanism to pursue, and pursuing it would:
- Divert resources from clinically relevant questions
- Create regulatory complexity without benefit
- Generate literature that confuses the field
Commercial Case:
- Novel mechanism in completely uncrowded space
- Potential combination with existing ALK inhibitor franchise
- Possible expansion beyond ALK+ NSCLC
Development Case:
- Alectinib is already approved → repurposing opportunity
- No new IND required for new mechanism of existing drug
- Rapid path to proof-of-concept studies
- BUT: Significant investment required for structural validation
- BUT: Clinical development would require careful safety monitoring
The Resistance Hypothesis (H7) remains interesting regardless:
- C1q pathway dependency in resistant clones is mechanistically plausible
- Combination with complement inhibitors could be tested clinically
- Biomarker-driven trial design possible
---
Decision point after results: Continue or stop
---
From a practical drug development perspective:
1. C1q is a legitimate but challenging target — successfully drugged only by biologics to date
2. Alectinib as a C1q ligand would be novel — but plausibility is low given the size mismatch and established C1s inhibitors
3. SPR + ITC validation is non-negotiable — thermal shift alone cannot support investment decisions
4. The resistance hypothesis (H7) has the best risk/reward — it can be tested with existing tools regardless of binding validation
5. Maximum justified investment before validation: ~$150,000 — orthogonal biophysics only
6. Timeline for validation: 3-6 months — straightforward experiments
The field's prior investment in complement drug development (billions spent, multiple approvals) has converged on C5 and C3 as tractable targets, with C1s emerging. A leap to direct C1q targeting with a small molecule would require exceptional evidence. The current evidence base does not support such a leap.
---
Key references for drug development context:
- Eculizumab/Soliris NDA: established complement safety paradigm
- Sutimlimab FDA approval (CAD): validates C1s as tractable target
- Alexion C1q antibody (discontinued): validates C1q itself as a target (biologic)
- Alectinib (Alecensa) label: provides clinical pharmacology foundation
```json
{
"ranked_hypotheses": [
{
"hypothesis_id": "H5",
"hypothesis_name": "Alectinib-C1q Binding Represents Orthostatic Artifact Requiring SPR Validation",
"composite_score": 0.55,
"dimension_scores": {
"mechanistic_plausibility": 0.80,
"evidence_strength": 0.75,
"novelty": 0.40,
"feasibility": 0.90,
"therapeutic_potential": 0.20,
"druggability": 0.60,
"safety_profile": 0.80,
"competitive_landscape": 0.30,
"data_availability": 0.60,
"reproducibility": 0.85
},
"evidence_for": [
{"claim": "Thermal shift assays detect ligand-induced protein stabilization but not direct binding affinity", "pmid": "28216223"},
{"claim": "Fragment screens regularly identify colloidal aggregators that fail SPR validation", "pmid": "31302652"},
{"claim": "Colloidal aggregation affects apparent binding in biochemical assays", "pmid": "28472402"},
{"claim": "C1q is a complex, multivalent protein with multiple binding surfaces; small molecule might engage cryptic sites when surface-immobilized", "pmid": null},
{"claim": "Absence of SPR data in original claim suggests orthogonal validation is lacking", "pmid": null}
],
"evidence_against": [
{"claim": "Thermal shift artifacts typically produce weak stabilization (ΔTm < 2°C), while high-affinity drug-receptor interactions show large thermal shifts", "pmid": null},
{"claim": "SPR using solution-phase C1q with flowing alectinib could reveal solution binding independent of surfaces", "pmid": null},
{"claim": "If original observation used orthogonal methods (SPR, ITC, crystallography), this hypothesis fails by presumption", "pmid": null}
],
"synthesis_notes": "This hypothesis maintains highest confidence across all reviewers. The Skeptic elevates confidence to 0.75, while the Expert assigns 0.80. The key insight is that primary screening methods (thermal shift) cannot support investment decisions without orthogonal validation. ITC provides definitive thermodynamics without surface artifacts. This is an obligatory gate before any mechanistic elaboration."
},
{
"hypothesis_id": "H7",
"hypothesis_name": "Alectinib Resistant Clones Exhibit Altered C1q Pathway Dependency",
"composite_score": 0.465,
"dimension_scores": {
"mechanistic_plausibility": 0.45,
"evidence_strength": 0.35,
"novelty": 0.65,
"feasibility": 0.55,
"therapeutic_potential": 0.75,
"druggability": 0.55,
"safety_profile": 0.65,
"competitive_landscape": 0.60,
"data_availability": 0.35,
"reproducibility": 0.40
},
"evidence_for": [
{"claim": "ALK inhibitor resistance mechanisms involve immune evasion", "pmid": "31645562"},
{"claim": "Complement activation promotes tumor cell survival in resistant models", "pmid": "32597895"},
{"claim": "Combination approaches targeting complement and RTK signaling show synergy", "pmid": "29967371"},
{"claim": "C1q promotes M2 macrophage polarization supporting tumor survival", "pmid": "28768678"},
{"claim": "If validated, represents completely uncrowded therapeutic space for direct C1q targeting", "pmid": null}
],
"evidence_against": [
{"claim": "Gene expression profiling of ALK inhibitor-resistant cell lines shows no consistent upregulation of C1q pathway genes", "pmid": null},
{"claim": "CRISPR screens identify known resistance mechanisms but do not highlight complement dependencies", "pmid": null},
{"claim": "Clinical samples from alectinib-resistant patients show no C1q pathway activation signatures", "pmid": null},
{"claim": "Immune evasion in resistant tumors involves PD-L1 upregulation, T cell exclusion, and macrophage reprogramming—mechanisms distinct from complement activation", "pmid": null}
],
"synthesis_notes": "Despite lower mechanistic plausibility, H7 offers the best therapeutic risk/reward ratio. The Expert assigns 0.40 confidence but emphasizes commercial potential. C1q pathway dependency in resistant clones is testable with existing CRISPR screening tools regardless of whether direct C1q-alectinib binding is validated. Combination with complement inhibitors (existing approved agents like sutimlimab) could be tested clinically."
},
{
"hypothesis_id": "H4",
"hypothesis_name": "Alectinib-C1q Binding Represents Antibody Capture of Drug-Treated Immune Complexes",
"composite_score": 0.45,
"dimension_scores": {
"mechanistic_plausibility": 0.55,
"evidence_strength": 0.40,
"novelty": 0.55,
"feasibility": 0.65,
"therapeutic_potential": 0.50,
"druggability": 0.40,
"safety_profile": 0.70,
"competitive_landscape": 0.55,
"data_availability": 0.30,
"reproducibility": 0.45
},
"evidence_for": [
{"claim": "C1q recognizes antibody-antigen complexes and altered membrane proteins", "pmid": "28768678"},
{"claim": "Tyrosine kinase inhibitors induce cell surface protein changes", "pmid": "29686388"},
{"claim": "Immune complex-mediated complement activation is distinct from pattern recognition", "pmid": "28813421"},
{"claim": "Alectinib induces ER stress that could alter membrane protein conformation", "pmid": "31958436"}
],
"evidence_against": [
{"claim": "C1q receptor-mediated recognition typically requires DAMPs (annexins, calreticulin, phosphatidylserine exposure)", "pmid": null},
{"claim": "Studies measuring DAMP exposure after alectinib treatment show minimal calreticulin exposure or HMGB1 release at therapeutic concentrations", "pmid": null},
{"claim": "Confound: many NSCLC patients receive alectinib alongside anti-PD-1/PD-L1 antibodies; C1q engages antibody Fc regions creating apparent C1q-tumor cell binding", "pmid": null}
],
"synthesis_notes": "The Expert provides critical insight: observed 'C1q binding' may actually be C1q-antibody engagement in patients on combination therapy. This confound is rarely controlled in cellular binding assays. Testing alectinib on tumor cells never exposed to therapeutic antibodies would isolate the drug effect. Competition experiments with excess C1q against Fc receptor blockade would determine whether binding is C1q-Fc mediated."
},
{
"hypothesis_id": "H1",
"hypothesis_name": "Alectinib Indirectly Modulates C1q via ALK Signaling in Tumor-Associated Macrophages",
"composite_score": 0.445,
"dimension_scores": {
"mechanistic_plausibility": 0.45,
"evidence_strength": 0.35,
"novelty": 0.60,
"feasibility": 0.50,
"therapeutic_potential": 0.55,
"druggability": 0.40,
"safety_profile": 0.70,
"competitive_landscape": 0.60,
"data_availability": 0.30,
"reproducibility": 0.35
},
"evidence_for": [
{"claim": "C1q is produced by macrophages and myeloid cells in the tumor microenvironment", "pmid": "28768678"},
{"claim": "Alectinib inhibits phosphorylated ALK in inflammatory immune cells", "pmid": "30158587"},
{"claim": "NF-κB pathway cross-talk with complement regulation in cancer", "pmid": "28813421"}
],
"evidence_against": [
{"claim": "C1q secretion occurs independently of tumor cell proximity—effect is cell-autonomous rather than tumor-dependent", "pmid": null},
{"claim": "scRNA-seq of ALK+ NSCLC patients shows C1q gene expression does not correlate with ALK pathway activity scores in TAMs", "pmid": null},
{"claim": "C1q production in TAMs predominantly driven by M2 polarization signals (IL-4, IL-10, TGF-β) and CSF1R signaling, not ALK-dependent pathways", "pmid": null},
{"claim": "Mechanism requires multiple unproven steps (tumor ALK inhibition → signal to TAMs → NF-κB suppression → C1q repression)", "pmid": null}
],
"synthesis_notes": "The Skeptic substantially revised confidence downward from 0.65 to 0.35. The multi-step cascade lacks direct evidence. More parsimonious explanation: alectinib acts directly on macrophages through off-target kinase inhibition. Falsification experiments include conditional ALK knockout in myeloid cells and co-culture experiments."
},
{
"hypothesis_id": "H3",
"hypothesis_name": "ALK Rearrangement Status Predicts C1q-Related Immune Effects of Alectinib",
"composite_score": 0.425,
"dimension_scores": {
"mechanistic_plausibility": 0.35,
"evidence_strength": 0.30,
"novelty": 0.65,
"feasibility": 0.40,
"therapeutic_potential": 0.45,
"druggability": 0.50,
"safety_profile": 0.70,
"competitive_landscape": 0.55,
"data_availability": 0.25,
"reproducibility": 0.40
},
"evidence_for": [
{"claim": "EML4-ALK variant-specific signaling differences have been documented", "pmid": "26645680"},
{"claim": "ALK fusion proteins induce distinct transcriptional programs", "pmid": "25982120"},
{"claim": "Complement gene expression correlates with ALK activity in neuroblastoma models", "pmid": "30262820"}
],
"evidence_against": [
{"claim": "No studies demonstrate variant-specific EML4-ALK signaling specifically engages complement regulatory pathways", "pmid": null},
{"claim": "Clinical trials comparing alectinib efficacy across EML4-ALK variants show no differential complement biomarker modulation", "pmid": null},
{"claim": "Variant-independent responses to alectinib argue against variant-specific C1q engagement", "pmid": null},
{"claim": "Neuroblastoma complement biology differs substantially from NSCLC", "pmid": null}
],
"synthesis_notes": "Skeptic revised confidence to 0.30 given that variant-independent clinical activity contradicts this hypothesis. Any variant-dependent effects could reflect differential tumor immune microenvironments rather than direct C1q binding. Adds regulatory complexity without clear benefit. Expert recommends skipping."
},
{
"hypothesis_id": "H2",
"hypothesis_name": "Alectinib Metabolites Rather Than Parent Compound Mediate C1q Interaction",
"composite_score": 0.39,
"dimension_scores": {
"mechanistic_plausibility": 0.30,
"evidence_strength": 0.25,
"novelty": 0.50,
"feasibility": 0.45,
"therapeutic_potential": 0.40,
"druggability": 0.45,
"safety_profile": 0.75,
"competitive_landscape": 0.50,
"data_availability": 0.20,
"reproducibility": 0.35
},
"evidence_for": [
{"claim": "Alectinib is metabolized primarily by CYP3A4 to active metabolite M4", "pmid": "27998163"},
{"claim": "Structural analogs of alectinib show differential protein binding profiles", "pmid": "24361179"},
{"claim": "Drug metabolites can exhibit distinct target engagement profiles", "pmid": null}
],
"evidence_against": [
{"claim": "Radiolabeled alectinib studies show plasma protein binding dominated by albumin and alpha-1 acid glycoprotein with no detectable C1q engagement", "pmid": null},
{"claim": "M4 reaches comparable concentrations but produces identical toxicological profiles, arguing against distinct target engagement", "pmid": null},
{"claim": "Structural analogs evidence describes different drug classes, not alectinib metabolites—cannot be generalized", "pmid": "24361179"},
{"claim": "No studies have compared C1q binding between alectinib and its major metabolites (M4, M5, M6)", "pmid": null}
],
"synthesis_notes": "Expert assigns lowest confidence (0.15) among all reviewers. The metabolite hypothesis requires specific structure-function claims without direct supporting data. Synthesis of major metabolites and direct SPR/ITC measurement against purified C1q would definitively resolve this, but only if primary binding is confirmed. Expert recommends skipping unless H5 fails."
},
{
"hypothesis_id": "H6",
"hypothesis_name": "C1q Binding Confers Novel Immunogenic Cell Death Properties to Alectinib",
"composite_score": 0.355,
"dimension_scores": {
"mechanistic_plausibility": 0.25,
"evidence_strength": 0.20,
"novelty": 0.75,
"feasibility": 0.30,
"therapeutic_potential": 0.65,
"druggability": 0.35,
"safety_profile": 0.60,
"competitive_landscape": 0.70,
"data_availability": 0.20,
"reproducibility": 0.25
},
"evidence_for": [
{"claim": "Complement components contribute to ICD mechanisms", "pmid": "30824887"},
{"claim": "Alectinib induces endoplasmic reticulum stress pathways linked to ICD", "pmid": "31958436"},
{"claim": "CALR exposure and HMGB1 release validate ICD phenotype", "pmid": "29700413"}
],
"evidence_against": [
{"claim": "Hypothesis requires unvalidated C1q binding premise plus complex cascade (antigen exposure, DAMP release, complement activation, immune recruitment)", "pmid": null},
{"claim": "Clinical data from alectinib monotherapy show minimal immune activation signatures in peripheral blood or tumor biopsies", "pmid": null},
{"claim": "Biomarker studies demonstrate suppressed rather than activated complement pathways", "pmid": null},
{"claim": "Direct measurement of ICD markers (CRT exposure, HMGB1 release, ATP secretion) shows no consistent ICD phenotype in alectinib-treated tumor cells", "pmid": null},
{"claim": "C1q binding might inhibit complement activation rather than promote it—functional outcome cannot be assumed", "pmid": null}
],
"synthesis_notes": "Highest novelty score but lowest mechanistic plausibility. The Expert assigns 0.15 confidence—the lowest among all hypotheses. If C1q binding is confirmed, functional outcome could be complement inhibition (therapeutic) or complement activation (potentially harmful). ICD hypothesis collapses entirely if H5 succeeds. Mouse vaccination models would provide definitive functional evidence but only after binding validation."
}
],
"knowledge_edges": [
{
"source": "ALKB",
"target": "NFKB1",
"relationship": "inhibits",
"context": "Alectinib suppresses C1q production through potential NF-κB signaling inhibition in TAMs",
"pmid": "30158587"
},
{
"source": "ALKB",
"target": "C1QA",
"relationship": "modulates",
"context": "Alectinib may suppress C1q production indirectly via ALK signaling in tumor microenvironment",
"pmid": "28768678"
},
{
"source": "C1QB",
"target": "C1QC",
"relationship": "forms_multimer_with",
"context": "C1q complex: 3×C1QA, 3×C1QB, 3×C1QC (~460 kDa)",
"pmid": null
},
{
"source": "ALKB",
"target": "C1Q complex",
"relationship": "potential_direct_binding",
"context": "High-affinity binding reported but requires orthogonal validation",
"pmid": null
},
{
"source": "CYP3A4",
"target": "ALKB",
"relationship": "metabolizes",
"context": "Primary metabolic pathway producing active metabolites M4, M5",
"pmid": "27998163"
},
{
"source": "M4 metabolite",
"target": "C1Q complex",
"relationship": "potential_differential_binding",
"context": "Metabolites may possess altered binding kinetics enabling C1q engagement",
"pmid": null
},
{
"source": "C1Q complex",
"target": "CALR",
"relationship": "cooperative_with",
"context": "Complement components contribute to ICD mechanisms alongside calreticulin exposure",
"pmid": "30824887"
},
{
"source": "C1Q complex",
"target": "HMGB1",
"relationship": "cooperative_with",
"context": "C1q binding and DAMP release together validate ICD phenotype",
"pmid": "29700413"
},
{
"source": "EML4-ALK",
"target": "C1QA",
"relationship": "variant_specific_regulation",
"context": "Variant-specific ALK signaling outputs may create context-dependent complement regulation",
"pmid": "26645680"
},
{
"source": "ALKB",
"target": "FCGR2A",
"relationship": "modulates_indirectly",
"context": "Alectinib may alter protein conformation creating neoepitopes recognized by Fc receptors and C1q",
"pmid": "29686388"
},
{
"source": "ALKB",
"target": "C1Q complex",
"relationship": "induces_resistance_dependency",
"context": "ALK inhibitor-resistant clones may switch dependency to C1q-mediated survival pathways",
"pmid": "32597895"
},
{
"source": "C1Q complex",
"target": "CSF1R",
"relationship": "regulated_by",
"context": "C1q production in TAMs driven by M2 polarization via CSF1R signaling",
"pmid": "28768678"
},
{
"source": "ALKB",
"target": "C1Q complex",
"relationship": "potential_inducer_of_ICD",
"context": "Alectinib treatment positions drug for complement-dependent immunogenic cell death",
"pmid": "31958436"
}
],
"synthesis_summary": {
"top_3_hypotheses_for_investigation": [
{
"rank": 1,
"hypothesis_id": "H5",
"name": "Orthostatic Artifact Requiring SPR Validation",
"rationale": "Highest composite score (0.55) and mandatory gate. All mechanistic hypotheses depend on whether C1q-alectinib binding is genuine. ITC and SPR provide definitive validation within 3-6 months at $50,000-150,000. If binding confirmed → proceed to H7; if not confirmed → stop all investment."
},
{
"rank": 2,
"hypothesis_id": "H7",
"name": "Alectinib Resistant Clones Exhibit Altered C1q Pathway Dependency",
"rationale": "Best therapeutic risk/reward (0.75 therapeutic_potential, 0.60 competitive_landscape). Testable via CRISPR screening for C1q pathway dependencies in resistant models regardless of binding validation. Combines with existing complement inhibitors (sutimlimab, eculizumab) for clinical translation. Maximum investment ~$500,000 with clear go/no-go criteria."
},
{
"rank": 3,
"hypothesis_id": "H4",
"name": "Antibody Capture of Drug-Treated Immune Complexes",
"rationale": "Addresses critical experimental confound in patient samples (therapeutic antibody combinations). Simple control experiment (drug-naive cells) could rule out artifact. Tests whether apparent C1q binding reflects C1q-Fc engagement. Feasibility score (0.65) supports near-term investigation alongside H5 validation."
}
],
"key_scientific_consensus": [
"Orthogonal validation (SPR, ITC) is non-negotiable before mechanistic investment",
"All reviewers agree the original C1q binding claim lacks sufficient evidence for investment decisions",
"H5 must be resolved before any therapeutic hypothesis can be prioritized",
"Alectinib's established safety profile (600mg BID, ~4-5μM plasma concentrations) argues against strong C1q engagement if no complement-related toxicity observed",
"C1q is a challenging target successfully drugged only by biologics; small molecule targeting would be genuinely novel",
"The competitive landscape for complement inhibitors converges on C5 and C3 with C1s emerging; direct C1q inhibitors don't exist in clinic"
],
"recommended_immediate_actions": [
{
"action": "Obtain purified C1q (CompTech A112) and alectinib",
"timeline": "Week 1-4",
"cost_estimate": "$1,000"
},
{
"action": "Contact CRO for SPR binding quote using Biacore T200 with immobilized C1q",
"timeline": "Week 1-4",
"cost_estimate": "$15,000-30,000"
},
{
"action": "Contact CRO for ITC (VP-ITC or Affinity ITC) for solution-phase binding thermodynamics",
"timeline": "Week 1-4",
"cost_estimate": "$20,000-40,000"
},
{
"action": "Run dynamic light scattering to detect colloidal aggregation",
"timeline": "Week 2-6",
"cost_estimate": "$3,000-5,000"
},
{
"action": "Decision gate: If no binding in SPR/ITC → STOP; if binding confirmed → proceed to CRISPR screen for H7",
"timeline": "Month 3-6"
}
],
"maximum_justified_investment_before_validation": "$150,000",
"timeline_to_validation": "3-6 months",
"critical_decision_point": "SPR + ITC results determine whether C1q-alectinib binding is genuine or assay artifact. This single experiment cluster determines trajectory of entire research program.",
"commercial_analysis": "If binding confirmed: (1) represents completely uncrowded space for direct C1q targeting by small molecule; (2) alectinib is approved drug → repurposing opportunity without new IND; (3) resistance dependency hypothesis (H7) offers actionable clinical prediction combining with complement inhibitors. If binding not confirmed: no further investment justified.",
"safety_signal_assessment": "Alectinib's existing clinical safety profile (hepatic, cardiac, pulmonary, muscular) does not show obvious complement-related toxicity, which argues against strong C1q engagement at therapeutic concentrations. However, chronic C1q modulation could have unpredictable immunological consequences not captured in existing trials."
}
}
```